Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Recurrence 2Squamous Cell Carcinoma of Head and Neck 1Rhabdomyosarcoma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1Lung Neoplasms 1Leiomyosarcoma 1Hodgkin Disease 1

Interventions

Gemcitabine 15Doxorubicin 8Docetaxel 8Radiotherapy 7Trabectedin 6Nivolumab 5pazopanib 4liposomal doxorubicin 3Sunitinib 3Dacarbazine 3pembrolizumab 2eribulin 2durvalumab 2avelumab 2Specimen Handling 2Radiation Dose Hypofractionation 2Letrozole 2Ifosfamide 2Bevacizumab 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2tremelimumab 1temsirolimus 1sotigalimab 1selinexor 1sargramostim 1rucaparib 1ribociclib 1regorafenib 1pegfilgrastim 1olaratumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leiomyosarcoma × mocetinostat × Clear all
NCT02303262 2019-01-29

SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma

Sarcoma Alliance for Research through Collaboration

Phase 2 Completed
20 enrolled 11 charts
Sarcoma

Leiomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡